These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 3082032)

  • 1. [Treatment of hemophiliacs with antibodies to factor VIII].
    Evensen SA; Stavem P; Stormorken H; Glomstein A; Ly B
    Tidsskr Nor Laegeforen; 1986 Jan; 106(1):35-8. PubMed ID: 3082032
    [No Abstract]   [Full Text] [Related]  

  • 2. [Factor VIII inhibitor in multitransfused hemophiliacs. A finding of varying therapeutic consequences].
    Ly B; Evensen SA; Stavem P
    Tidsskr Nor Laegeforen; 1977 Apr; 97(12):554-6, 8. PubMed ID: 854906
    [No Abstract]   [Full Text] [Related]  

  • 3. Prothrombin complex concentrates in hemophiliacs with inhibitors--a multicenter therapeutic trial.
    Lusher JM; Shapiro SS; Palascak JE; Rao AV; Levine PH; Blatt PM
    Trans Assoc Am Physicians; 1980; 93():175-81. PubMed ID: 6787773
    [No Abstract]   [Full Text] [Related]  

  • 4. Anal intercourse as a possible factor in heterosexual transmission of HTLV-III to spouses of hemophiliacs.
    Melbye M; Ingerslev J; Biggar RJ; Alexander S; Sarin PS; Goedert JJ; Zachariae E; Ebbesen P; Stenbjerg S
    N Engl J Med; 1985 Mar; 312(13):857. PubMed ID: 2983213
    [No Abstract]   [Full Text] [Related]  

  • 5. [Treatment of hemophiliacs with inhibitors].
    Fujimaki M
    Rinsho Ketsueki; 1985 Jul; 26(7):1059-68. PubMed ID: 3932719
    [No Abstract]   [Full Text] [Related]  

  • 6. Immunologic safety of recombinant factor VIII. The rFactor VIII Clinical Trial Group.
    Abildgaard CF
    Semin Hematol; 1991 Apr; 28(2 Suppl 1):44. PubMed ID: 1908127
    [No Abstract]   [Full Text] [Related]  

  • 7. [Importance of corticoids in inhibitor suppression in hemophilia A, in addition to continuing treatment with factor VIII concentrate].
    Aznar JA; Jorquera JI; Marty ML
    Sangre (Barc); 1983; 28(3):265-79. PubMed ID: 6414098
    [No Abstract]   [Full Text] [Related]  

  • 8. Early experience with the use of anti-inhibitor coagulant complex to treat bleeding in hemophiliacs with inhibitors to factor VIII.
    Kantrowitz JL; Lee ML; McClure DA; Kingdon HS; Thomas WR
    Clin Ther; 1987; 9(4):405-19. PubMed ID: 3111706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Curves of factor VIII activity in the plasma of hemophiliacs after injection of 500 units of lyophilized factor VIII].
    Zanichelli M; Carelli Cde R; Coelho E; Salem MZ
    AMB Rev Assoc Med Bras; 1982; 28(11-12):261-3. PubMed ID: 6820526
    [No Abstract]   [Full Text] [Related]  

  • 10. Short incubation non-A, non-B hepatitis transmitted by factor VIII concentrates in patients with congenital coagulation disorders: a preliminary report of an antigen/antibody system.
    Bamber M; Murray A; Kernoff PB; Thomas HC
    Med Lab Sci; 1981 Oct; 38(4):373-8. PubMed ID: 6799726
    [No Abstract]   [Full Text] [Related]  

  • 11. [Safe and cost-conscious supply of factor-VIII-deficient Swiss hemophiliacs with AHF preparations].
    Stampfli K
    Ther Umsch; 1977 Oct; 34(10):717-24. PubMed ID: 918896
    [No Abstract]   [Full Text] [Related]  

  • 12. Parvovirus B19 antibodies in patients with haemophilia A.
    Peerlinck K; Goubau P; Reybrouck R; Desmyter J; Vermylen J
    Thromb Haemost; 1995 Mar; 73(3):555-6. PubMed ID: 7667846
    [No Abstract]   [Full Text] [Related]  

  • 13. Extracorporeal protein A-sepharose and specific affinity chromatography for removal of antibodies.
    Nilsson IM; Sundqvist SB; Freiburghaus C
    Prog Clin Biol Res; 1984; 150():225-41. PubMed ID: 6431430
    [No Abstract]   [Full Text] [Related]  

  • 14. Prevalence of hepatitis B and C seromarkers and abnormal liver function tests among hemophiliacs in Guilan (northern province of Iran).
    Mansour-Ghanaei F; Fallah MS; Shafaghi A; Yousefi-Mashhoor M; Ramezani N; Farzaneh F; Nassiri R
    Med Sci Monit; 2002 Dec; 8(12):CR797-800. PubMed ID: 12503038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitor development in haemophilia A patients with inversion of the intron 22 of the factor VIII gene.
    Tizzano EF; Altisent C; Domènech M; Cornet M; Tusell J; Baiget M
    Thromb Haemost; 1996 Jul; 76(1):125-6. PubMed ID: 8819266
    [No Abstract]   [Full Text] [Related]  

  • 16. Is a change of factor VIII product a risk factor for the development of a factor VIII inhibitor?
    Baglin T; Beacham E
    Thromb Haemost; 1998 Dec; 80(6):1036-7. PubMed ID: 9869186
    [No Abstract]   [Full Text] [Related]  

  • 17. The natural history of factor VIII inhibitors in patients with hemophilia A.
    Gill FM
    Prog Clin Biol Res; 1984; 150():19-29. PubMed ID: 6431427
    [No Abstract]   [Full Text] [Related]  

  • 18. Hemophilic patients with an inhibitor to factor VIII treated with high dose factor VIII concentrate. Results of a collaborative study for the evaluation of factor VIII inhibitor titer, recovery and half life of infused factor VIII.
    Sultan Y; White GC; Aronstam A; Bosser C; Brackmann HH; Brochier G; Gormsen J; Mariani G; Roberts HR; Scarabin Y
    Nouv Rev Fr Hematol (1978); 1986; 28(2):85-9. PubMed ID: 3090516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Anti-HTLV-III antibodies in hemophiliacs treated with concentrates of factors VIII or IX].
    Aznar JA; Granda D; Jorquera J; González-Molina A; Carmona E; Peiró A; Gobernado M
    Sangre (Barc); 1985; 30(5):934-5. PubMed ID: 3937254
    [No Abstract]   [Full Text] [Related]  

  • 20. Immune response induced by porcine factor VIII in severe hemophiliacs with antibody to F VIII.
    Verroust F; Allain JP
    Thromb Haemost; 1982 Oct; 48(2):238. PubMed ID: 6817447
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.